These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8120520)

  • 1. Metabolic remission with octreotide in patients with insulinoma.
    von Eyben FE; Grodum E; Gjessing HJ; Hagen C; Nielsen H
    J Intern Med; 1994 Mar; 235(3):245-8. PubMed ID: 8120520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No effect of the long-acting somatostatin analogue octreotide in patients with insulinoma.
    Timmer R; Koningsberger JC; Erkelens DW; Thijssen JH; Lips CJ; Koppeschaar HP
    Neth J Med; 1991 Jun; 38(5-6):199-203. PubMed ID: 1922592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of insulinoma by a single daily dose of octreotide in two elderly female patients.
    Kishikawa H; Okada Y; Hirose A; Tanikawa T; Kanda K; Tanaka Y
    Endocr J; 2006 Feb; 53(1):79-85. PubMed ID: 16543676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amelioration of hypoglycemia with octreotide therapy in metastatic insulinoma with positive octreotide scan.
    Wade AN; Cheng G; Teitelbaum U; Patel AA; Alavi A; Rickels MR
    Pancreas; 2011 Jan; 40(1):173-5. PubMed ID: 21160385
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.
    Glaser B; Rösler A; Halperin Y
    Isr J Med Sci; 1990 Jan; 26(1):16-9. PubMed ID: 2155884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the long-acting somatostatin analogue octreotide in the management of insulinoma in three dogs.
    Simpson KW; Stepien RL; Elwood CM; Boswood A; Vaillant CR
    J Small Anim Pract; 1995 Apr; 36(4):161-5. PubMed ID: 7603057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Benign insulinoma. Efficacy of preoperative treatment for persistent hyperinsulinemia using a synthetic somatostatin analog].
    Esposito V; Esposito D; Lo Iudice G; Rispoli C; Verrillo A; D'Alessandro B
    Minerva Endocrinol; 1994 Mar; 19(1):33-7. PubMed ID: 8035768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin).
    Stehouwer CD; Lems WF; Fischer HR; Hackeng WH; Naafs MA
    Acta Endocrinol (Copenh); 1989 Jul; 121(1):34-40. PubMed ID: 2545062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful long-term treatment with once-daily injection of low-dose octreotide in an aged patient with insulinoma.
    Katabami T; Kato H; Shirai N; Naito S; Saito N
    Endocr J; 2005 Oct; 52(5):629-34. PubMed ID: 16284444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of symptoms of chemotherapy-refractory metastatic insulinoma using octreotide.
    Longnecker SM
    Drug Intell Clin Pharm; 1988 Feb; 22(2):136-8. PubMed ID: 2894965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-responsive and octreotide-sensitive insulinoma.
    Izumiyama H; Gotyo N; Fukai N; Ozawa N; Doi M; Yoshimoto T; Arii S; Hirata Y
    Intern Med; 2006; 45(8):519-24. PubMed ID: 16702744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible functional regression of insulinoma with prolonged octreotide.
    Craig CE; Gallen IW
    Postgrad Med J; 2002 Oct; 78(924):623-4. PubMed ID: 12415090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones.
    Osei K; O'Dorisio TM
    Ann Intern Med; 1985 Aug; 103(2):223-5. PubMed ID: 2861769
    [No Abstract]   [Full Text] [Related]  

  • 14. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.
    Vezzosi D; Bennet A; Rochaix P; Courbon F; Selves J; Pradere B; Buscail L; Susini C; Caron P
    Eur J Endocrinol; 2005 May; 152(5):757-67. PubMed ID: 15879362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.
    Romeo S; Milione M; Gatti A; Fallarino M; Corleto V; Morano S; Baroni MG
    Horm Res; 2006; 65(3):120-5. PubMed ID: 16479142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case.
    Tanaka Y; Funahashi H; Imai T; Naruse T; Suzumura K; Oda Y
    Surg Today; 2000; 30(6):541-3. PubMed ID: 10883468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of SMS 201-995 (somatostatin analogue) in insulinomas. Additional case report and literature review.
    Hearn PR; Ahmed M; Woodhouse NJ
    Horm Res; 1988; 29(5-6):211-3. PubMed ID: 2851522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of benign insulinoma using octreotide LAR: a case report.
    Usukura M; Yoneda T; Oda N; Yamamoto Y; Takata H; Hasatani K; Takeda Y
    Endocr J; 2007 Feb; 54(1):95-101. PubMed ID: 17124362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of plasma glucose with somatostatin analogue (SMS 201-995) during surgical removal of insulinomas.
    Utas C; Kelestimur F; Boyaci A; Saglam A
    Postgrad Med J; 1993 Dec; 69(818):920-1. PubMed ID: 8121865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
    Arnold R; Frank M; Kajdan U
    Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.